D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 7.175 USD 3.39%
Market Cap: 727.3m USD

Operating Margin
Day One Biopharmaceuticals Inc

-51.6%
Current
-307%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-51.6%
=
Operating Profit
-83.6m
/
Revenue
161.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
727.2m USD
-52%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.2B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
145B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
130.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.1B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Day One Biopharmaceuticals Inc
Glance View

Market Cap
727.2m USD
Industry
Biotechnology

Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs. Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.

DAWN Intrinsic Value
17.532 USD
Undervaluation 59%
Intrinsic Value
Price
D
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-51.6%
=
Operating Profit
-83.6m
/
Revenue
161.9m
What is the Operating Margin of Day One Biopharmaceuticals Inc?

Based on Day One Biopharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -51.6%.

Back to Top